tiprankstipranks
Biotech Alert: Searches spiking for these stocks today
The Fly

Biotech Alert: Searches spiking for these stocks today

Stay ahead of biotech stocks seeing a surge in interest from retail and financial professional investors with this exclusive recap from The Fly

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:

  • Y-mAbs Therapeutics (YMAB), 6,633% surge in interest
  • Spero Therapeutics (SPRO), 1,007% surge in interest
  • Checkpoint Therapeutics (CKPT), 219% surge in interest
  • Paratek Pharmaceuticals (PRTK), 199% surge in interest
  • BrainStorm Cell Therapeutics (BCLI), 18% surge in interest

Pipeline and key clinical candidates for these companies:

Y-mAbs is focused on the development and commercialization of novel, antibody-based therapeutic cancer products. In addition to conventional antibodies, the company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform. The company’s product pipeline includes one FDA-approved product, Danyelza, which targets tumors that express GD2, and one product candidate at the registration-stage, Omblastys, which targets tumors that express B7-H3.

Spero Therapeutics is focused on identifying, developing, and commercializing novel treatments for serious bacterial infections, including MDR bacterial infections and rare diseases. Spero is developing SPR720 as a novel investigational oral candidate antimicrobial for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections. Tebipenem HBr is an investigational oral carbapenem candidate antimicrobial in development for the treatment of cUTI, including pyelonephritis, including infections caused by MDR pathogens in adult patients who have limited oral treatment options; tebipenem HBr is not FDA-approved. Spero Therapeutics is developing SPR206 as an investigational intravenous-administered next-generation polymyxin product candidate developed from its potentiator platform, which is in development to treat MDR Gram-negative infections in the hospital setting.

Checkpoint Therapeutics is focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma, or “cSCC,” intended to support one or more applications for marketing approval. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, formerly CK-101, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Paratek Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. The company’s lead commercial product, Nuzyra, is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights. Paratek is also conducting a Phase 2b study with Nuzyra in a rare disease, nontuberculous mycobacterial pulmonary disease, caused by Mycobacterium abscessus complex. Paratek estimates this opportunity represents a potential $1B addressable market in the United States.

BrainStorm Cell Therapeutics is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The company holds the rights to clinical development and commercialization of the NurOwn technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement. Autologous MSC-NTF cells have received Orphan Drug designation status from the FDA and the EMA for the treatment of amyotrophic lateral sclerosis, ALS. BrainStorm has completed a Phase 3 pivotal trial in ALS; this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells and was supported by a grant from the California Institute for Regenerative Medicine.

Recent news on these stocks:

April 3

Guggenheim downgraded Y-mAbs Therapeutics to Neutral from Buy and removed the firm’s prior $12 price target, citing current progress with the GD2-SADA clinical trial. While the firm remains "intrigued by the SADA approach" that aims to selectively localize radiation within tumors, it has grown increasingly cautious given the rate of patient recruitment and is removing GD2-SADA from its estimates pending additional clarity. The firm adds that potential label expansions may potentially not occur in the near-term and it is uncertain if Danyelza’s current label can bring the company to EPS positivity.

Ladenburg lowered the firm’s price target on Checkpoint Therapeutics to $69 from $96 and keeps a Buy rating on the shares, citing dilution associated with recent capital raises for the lower target. Cosibelimab’s BLA being accepted for metastatic and locally advanced cutaneous squamous cell carcinoma is "a significant milestone," the analyst tells investors.

March 30

Spero Therapeutics reported Q4 EPS 55c against a consensus of 4c. Reports Q4 revenue $47.4M against a consensus of $22.87M."We were pleased to recently initiate our Phase 2 trial of Spero reported net income of $26.8M for the fourth quarter and an overall net loss of $46.4M, for the year ended December 31 , or a net income of 55c and net loss of $1.23 per share of common stock, respectively. Net loss for the fourth quarter and year ended December 31, 2021, was $29.2M and $89.8M, or 90c and $2.91 per share of common stock, respectively.SPR720 in NTM-PD," said Ankit Mahadevia, M.D., CEO of Spero Therapeutics.

March 27

BrainStorm announced that the FDA will hold an Advisory Committee Meeting, or ADCOM, to discuss the company’s Biologics License Application, or BLA, for NurOwn for the treatment of amyotrophic lateral sclerosis, or ALS. Given the goal to proceed to an ADCOM as expeditiously as possible, BrainStorm requested that the Center for Biologics Evaluation and Research utilize the FDA’s File Over Protest procedure and has filed an amendment to the BLA which responds to most of the outstanding questions the FDA has posed. "The FDA provided us with more than one path to an ADCOM for NurOwn. Our goal has always been to make NurOwn available to people living with ALS as quickly as possible, therefore we chose the File Over Protest pathway since this offered the fastest path to an ADCOM and regulatory decision relative to other pathways provided by the FDA," said Chaim Lebovits, President and CEO of BrainStorm. "The ALS community needs additional treatment options now, and we firmly believe our data support regulatory approval of NurOwn. We are grateful to the FDA for the opportunity to have the clinical evidence supporting NurOwn reviewed."


About “Biotech Alert”

The Fly will report on a selection of biotech stocks seeing a surge in interest from retail and financial professional investors, based on data from InvestingChannel.

This Fly exclusive recap reveals the biotech stocks that are seeing a spike in searches among the 15-plus million retail and financial professional investors through InvestingChannel’s online financial news media ecosystem.

This increased attention from the investors may be in response to, or advance of, outsized moves for stocks in the biotech sector, which tend to be volatile and prone to sharp swings in share price around binary events such as clinical study results and FDA approvals.

Keywords: biotech, biotech sector, biotech alert, investingchannel, XBI, SPDR S&P Biotech ETF

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on BCLI:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles